Abstract
In the last decade radiotracers have been gradually growing in importance as aids for the development of new drugs. This development has been most pronounced for Psychiatric and Neurologic drugs [1, 2], but has more recently been adapted to the development of drugs against cancer. In this mini-review, we describe how advances in molecular imaging of cancer are likely to lead to advances in development and improved application of anti-cancer drugs [3]. We will focus on 4 aspects of use of radiotracers: 1) for treatment response assessment; 2) for the study of kinetics and pharmacology of novel drugs, including bioavailability and local tumor concentration; 3) the identification of the biologic target at the cellular level; 4) the combination of nanocarriers and radioisotopes to improve biodistribution.
Keywords: Drug Development, radiotracers, molecular imaging, anti-cancer drugs, Cancer Biology
Current Pharmaceutical Design
Title: Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Volume: 15 Issue: 9
Author(s): Steven M. Larson
Affiliation:
Keywords: Drug Development, radiotracers, molecular imaging, anti-cancer drugs, Cancer Biology
Abstract: In the last decade radiotracers have been gradually growing in importance as aids for the development of new drugs. This development has been most pronounced for Psychiatric and Neurologic drugs [1, 2], but has more recently been adapted to the development of drugs against cancer. In this mini-review, we describe how advances in molecular imaging of cancer are likely to lead to advances in development and improved application of anti-cancer drugs [3]. We will focus on 4 aspects of use of radiotracers: 1) for treatment response assessment; 2) for the study of kinetics and pharmacology of novel drugs, including bioavailability and local tumor concentration; 3) the identification of the biologic target at the cellular level; 4) the combination of nanocarriers and radioisotopes to improve biodistribution.
Export Options
About this article
Cite this article as:
Larson M. Steven, Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787581959
DOI https://dx.doi.org/10.2174/138161209787581959 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exposing “Bright” Metals: Promising Advances in Photoactivated Anticancer Transition Metal Complexes
Current Medicinal Chemistry Poly-Pharmacy Among the Elderly: Analyzing the Co-Morbidity of Hypertension and Diabetes
Current Pharmaceutical Design Cancer Control by Phytochemicals
Current Pharmaceutical Design Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Angiotensin-Converting Enzymes (ACE and ACE2) as Potential Targets for Malignant Epithelial Neoplasia: Review and Bioinformatics Analyses Focused in Oral Squamous Cell Carcinoma
Protein & Peptide Letters Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Development of Focal Adhesion Kinase Inhibitors in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents
Mini-Reviews in Medicinal Chemistry PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design